NanoViricides Launches Patient Enrollment in Phase II Ebola Trial

Release - Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - Channelchek

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo (“DRC”) has started enrolling and dosing patients at an Ebola Treatment Center in the Ituri province.

NanoViricides Launches Patient Enrollment in Phase II Ebola Trial

NanoViricides has begun enrolling and dosing patients in a Phase II clinical trial of NV-387 Oral Gummies for Ebola, marking a critical step in developing a broad-spectrum antiviral. The post NanoViricides Launches Patient Enrollment in Phase II Ebola Trial appeared first on citybuzz.